title: [Promising results of bimonthly chemotherapy with high dose cyclophosphamide and epirubicin in induction treatment of inflammatory cancer of the breast].
abstract: Forty-eight patients with inflammatory breast cancer were treated by an induction regimen with cyclophosphamide (1200 mg/m2), and epirubicin (75 mg/m2). Four to six courses were given every two weeks, whatever the absolute leukocyte counts, before mastectomy, loco-regional radiation, and conventional, or reinforced, for selected patients, chemotherapy. Main toxicity was leukopenia, with grade IV in 25% of cases. However, febrile neutropenia was rare, and relative dose intensity was 102% after four courses, and 97% after six courses. Complete disappearance of inflammatory signs was observed in 90% of patients. Three patients had a pathological complete response, and ten patients had negative axillary lymph nodes. Furthermore, 13 patients had a major pathological response. With a median follow-up of 42 months, progression-free survival and overall survival are 48% and 66%, respectively.
authors.affiliation: Service d'oncologie médicale, hôpital Saint-Louis, Paris, France.
authors.forename: S
authors.initials: S
authors.lastname: Culine
authors.forename: J M
authors.initials: JM
authors.lastname: Extra
authors.forename: M
authors.initials: M
authors.lastname: Espie
authors.forename: E
authors.initials: E
authors.lastname: Bourstyn
authors.forename: V
authors.initials: V
authors.lastname: Dieras
authors.forename: S
authors.initials: S
authors.lastname: Giacchetti
authors.forename: C
authors.initials: C
authors.lastname: Maylin
authors.forename: A
authors.initials: A
authors.lastname: De Rocquancourt
authors.forename: F
authors.initials: F
authors.lastname: Morvan
authors.forename: M
authors.initials: M
authors.lastname: Marty
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D002648:Child; D003520:Cyclophosphamide / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D015409:Mastectomy, Radical; D008875:Middle Aged; D009367:Neoplasm Staging; D015996:Survival Rate
chemical_list: D015251:Epirubicin; D003520:Cyclophosphamide
vernacular_title: Résultats prometteurs d'une chimiothérapie bimensuelle avec cyclophosphamide et épirubicine à forte dose dans le traitement d'induction du cancer du sein inflammatoire.